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Ten hybridoma cell lines prodacing monoclonaI antibodies (Mabs) against M. avium/intrace-
llulare (Mai) serotype 8 were raised by the fusion of BALB/c mouse myeloma cells
(SPZ) to spleen cells from immunized BALB/c mice.The specificity of the monoclonal
antibodies was defined using their differing abilities to bind to sonicates from a range of
mycobacterial species and strains.Tbe Mabs showed strain and species specificity.Three
Mabs bound only to Mai serotype 8 and 1 Mab bound only to Mai serotypes 8 and 16, the
only serotypes tested.The results indicate that Mabs specific for Mai species and sero-
types can be produced. These could be useful for serodiagnostic and for epidemiological
Organisms of the Mycobacterium avium/
intracellulare complex (Mai) are of fairly
frequent occurrence in man, especially in
countries such as India1, where either they
colonise the tracheal mucosa or more rarely
are responsible for disease. Monoclonal
antibodies (Mabs) specific for Mai could
therefore be of value in the study of myco-
bacterial disease. Firstly, their high speci-
ficity might be used to subdivide species for
epidemiological purposes.Secondly, the
Mabs could form the basis of serodiagnostic
tests specific for Mai infection, which is
posing an increasing problem in immunocom-
promised persons, particularly those with
AIDS. Thirdly, the Mabs might be used to
isolate the specific epitopes from Mai anti-
gen. These molecules could then be in-
valuable in testing the hypothesis that prior
exposure to environmental Mai impairs the
fficacy of BCG vaccination2,3. Mai is
likely to be more important as an environ-
mental immunogen than other mycobacteria,
because it was the most frequent non-tuber-
culosis mycobacterium isolated from sputum
in the south Indian region where BCG vacci-
nation was found to give poor protection1,4.
Material & Methods
Bacteria : M. avium/intracellulare serotype 8
(NCTC 10610) and serotype 16 (NCTC
10425) were used M. tuberculosis strains
were the laboratory strain H37Rv (phage
13
type B), strain S1 (isoniazid-sensitive, phage
type A) obtained before chemotherapy from
a British patient and strain 7219 (isoniazid-
sensitive; low virulence in the guineapig, with
a rootindex of virulence of 0.57; phage type I)
from a south Indian patient.Strains of M.
bovis were Vallee (NCTC 5693) and BCG-
Glaxo (both phage type A). Other bacteria
were M. scrofulaceum (NCTC 10803), M.
kansasii (NCTC 10268), M. gordonae
(NCTC 10267), M. flavescens (NCTC 10271),
M. terrae (NCTC 10856), M. fortuitum
(NCTC 10394),M. chelonei (abscessus)
(NCTC 10882) and Escherichia coli strain
K12.
Antigen preparation : Antigens used for
immunisation and screening were ultrasonic
lysates of mycobacteria. The mycobacterial
cultures were grown on the surface of liquid
Sauton’s medium until confluent colonies were
just apparent. The cultures were then har-
vested and sonicated in phosphate buffered
saline (Dulbecco ‘A’) in an ice bath for 15
min (in 5 sec bursts) using a Rinco Model
MP ultrasonicator (Rinco Ultrasonics UK
Ltd., London) at 70 per cent maximum
intensity. After ultracentrifugation of the
lysates at 100,000 g for 1 h (Kontron Instru-
ments; Switzerland) the supernatants were
sterilised by filtration (0.22 pm Millipore,
SLGV membrane) and adjusted to a standard
protein content as determined by a modified
Lowry’s method with tartrate replaced by
citrate5.
Immunisation and fusion : BALB/c mice were
immunised ip with Mai serotype 8 antigen
containing 100 µg protein with incomplete
Freund's adjuvant on days 0 and 15. Ten
days after the second inoculation, sera from
the mice were tested for antibody activity
against Mai serotype 8 using solid phase
radioimmunoassay (RIA) as described pre-
viously6. Mice which showed high levels of
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antibody were selected and a third injection,
with ut adjuvant, was given ip three days
before harvesting the spleen cells for fusion.
Polyethylene glycol mediated fusions were
done with the mouse myeloma cell line SP27.
The culture supernatants from numerous
hyb ds were initially tested by RIA against
sonicates of Mai serotype 8 and Esch. coli,
to determine the broad specificity of the
clones. After two limiting dilutions, 14
clones were selected and fuller specificities
were determined by testing their culture
supernatants against sonicates of the 14
mycobacterial species and Esch. coli. Of
these clones, 10 which showed diverse speci-
ficities were injected ip into pristane-
primed mice to induce antibody-rich ascites
and each ascitic fluid sample was also tested
for specificity.
Characterisation studies : The monoclonal
antibodies (Mabs) were further characterised
by determining their immunoglobulin iso-
types by immunofluorescent staining of the
clones. Three clone supernatants were
selected forimmunoblotting to determine
the approximate molecular weight of the
antigenic proteins to which the Mabs bound
and to confirm the specificities shown by solid
phase RIA8. Blotting was against the myco-
bacterial sonicates that had been run on
sodium dodecylsulphate-polyacrylamide slab
gel electrophoresis (SDS-PAGE) under redu-
cing conditions9.
Results
Th  binding of ascitic fluid rich in Mab
AI/1 to the antigen sonicate of Mai serotype
8 as well as the control binding to the plastic
well is show in the Fig., and is representative
of all of the curves obtained with the ascitic
fluids, Based on such titrations, each ascitic
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Fig. Titration curves of binding of monoclonal anti-
body AI/10 (ascitic fluid) to (a) sonicate of Mai sero-
type 8 (O–O), (b) to empty plastic wells ( l – l )
and net binding ( n – n , a–b). Binding is expressed
as a percentage in relation to a control well coated
with normal mouse serum (100% reference).
fluid was diluted to an extent (to 10-4; in
Fig.) consistent with retaining net binding of
antibody to Mai serotype 8 antigen that was
at least 20 per cent of the values for normal
mouse serum-coated wells (i.e.,percentage
binding >20%). The ascitic fluid was then
assayed at this dilution for cross-reactivity
with other mycobacterial sonicates.
The binding patterns and antibody isotypes
for ascitic fluids from 10 hybridomas are
shown in the Table. The binding of these
Mabs suggested 6 distinct patterns. The
first is shown by a group, containing AI/4,
AI/6 and AI/7, binding only to Mai serotype
8 and not to any of the other mycobacterial
antigens including Mai serotype 16; AI/2
shows species specificity in that it bound
only to the Mai strains tested and not even
to the antigenically closely related M.
scrofulaceum; the third pattern was shown
by AI/5 and AI/8, which reacted only with
Mai serotype 8 and, to a low degree, M.
tuberculosis H37Rv; in contrast, AI/l bound
slightly to M. bovis BCG in addition to Mai
serotype 8 ; the fifth pattern is shown by AI/3,
which bound to Mai serotype 8, M. bovis
Vallee and M. fortuitum. AI/9 bound to
about half to the mycobacterial sonicates
tested and AI/10 reacted positively with all
of them.
The binding patterns for all 10 Mabs were
also assessed using undiluted supernatant
from tissue culture wells and there was good
agreement with results from ascitic fluids.
Further, assays of subclones of AI/9 (to
confirm purity of AI/9) were in close agree-
ment with the results shown.
In immunoblotting, AI/10, which bound
to all of the mycobacterial antigens tested by
RIA, bound uniformly to a common antigen
of approximately 45 kdaltons. AI/8,
chosen for its RIA specificity for Mai serotype
8 and to M. tuberculosis H37Rv, bound
selectively to an antigen of molecular weight
of approximately 110 kdaltons that appeared
to be present only in blots prepared from
extracts of these two organisms.AI/7 bound
only to an antigen of approximately 90
kdaltons in Mai serotype 8 blots.
Discussion
Discrimination between mycobacterial
trains and species was achieved with 9 of
the 10 Mabs (Table), though more strains
should be tested before firm conclusions on
specificity of these Mabs can be reached.
Mabs that distinguish between Mai serotypes
4, 8 and 9 have recently been reported10.
Of particular interest was the ability of most
of our Mabs to differentiate between Mai
serotype 8 and serotype 16. Our evidence
is insufficient to conclude whether or not
AI/4 and AI/6 bind to the Schaefer antigen
of serotype 8 which is a small peptidogly-
colipid11. In contrast, it seems unlikely
that AI/7 reacts with the Schaefer antigen
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Table. Specificity of monoclonal antibodies†
Antigen
Monoclonal antibody
AI/4 AI/6 AI/7 AI/2 AI/5 AI/8 AI/1 AI/3 AI/9 AI/10
M. avium/intracellulare (s rotype 8) 41 78
* *
* *
31
**
*
31
12
*
*
*
**
*
**
*
**
*
*
*
*
*
2a
21
*
*
16
*
*
24
*
*
41
*
*
*
**
**
10
*
*
M. intracellulare (serotype 16)
M. scrofulaceum
M. tuberculosis
H37Rv * *
SI * *
7219 * *
M. bovis
Vallee * *
BCG * *
M. kansasii * *
M. flavescens * *
M. gordonae * *
M. terrae * *
M. fortuitum ** *
M. chelonei * *
Esch. coli * *
Isotype 2a 2a
† Percentage binding, defined as described in the text, is‘ shown only for positive reactions (binding of > 10 %).
** 5–9.9 % binding;* < 5% binding
*
*
*
*
*
**
*
*
*
2b 2b
10
*
*
*
*
**
*
*
*
**
*
*
3
*
*
*
**
*
*
*
11
*
*
*
*
*
*
*
13
*
*
*
*
**
16
*
*
2a 2a
54 100
** 25
14 32
** 26
** 20
19 2.5
41 27
19 24
** 38
52 35
** 39
* 30
52 30
76 61
* *
1 1
because immunoblotting revealed that this
Mab binds to a 90,000 dalton molecule.
Further, this antigen was detected as a single
band with protein stains such as Coomassie
blue and Amido black. It is nevertheless
possible that it contains the antigenic
carbohydrate residues present in the Schaefer
antigen and that the Mab binds to this
carbohydrate epitope.
Isolation of antigens with Mabs such as
these would open two important avenues
of research into the reasons for the relative
failure of the BCG trial in south India.
For example, a Mab such as AI/2 could be
used to purify an antigen with an epitope
shared between several serotypes of M.
avium/intracellularebut absent in other
sp cies of mycobacteria. If this antigen
was more specific for Mai than PPD B it
could be useful as a skin test reagent or as a
stimulant of circulating T lymphocytes to
establish the incidence of exposure of indi-
viduals in south India to Mai. However,
if thi  antigen was a large protein molecule
it would probably bear many different
epitop s, some of which could be present
in other mycobacteria and thus compromise
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the specificity of the AI/2 epitope. In this
situation fractionation of the molecule might
yield the specific epitope. Secondly, anti-
gens isolated by Mabs AI/9 or AI/10 would
bear epitopes which were shared between
Mai, M. bovis BCG and M. tuberculosis. One
of the hypotheses to explain the low protec-
tive value of BCG vaccination in south
India, is that exposure to environmental
mycobacteria, likely to be Mai, provides a
degree of immunity which cannot be in-
creased by subsequent BCG vaccination.
An exploration of any interaction between
shared epitopes and the specific epitope in
protective cellular immunity might help to
clarify the basis of success and failure in
BCG vaccination.
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